ValuentumAd

Official PayPal Seal

Johnson & Johnson Revises Sales Guidance Higher Yet Again

publication date: Jul 16, 2019
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Image Shown: Johnson & Johnson revised its expected sales growth rate for 2019 upwards, however, pressures on its operating margin forced management to keep adjusted EPS forecasts the same. Image Source: Johnson & Johnson – IR Presentation. 

Consumer packaged goods and healthcare giant Johnson & Johnson, a holding in both our simulated Best Ideas Newsletter and Dividend Growth Newsletter portfolios, reported second-quarter 2019 earnings July 16 that received mixed reviews from the market. Shares of JNJ initially sold off before recovering later in the trading day.


Subscribe Now to Gain Access!

This page is available to subscribers only. To gain access to members only content (including this research piece), click here to subscribe. With a subscription, you'll have access to all of our premium commentary, equity reports, dividend reports and Best Ideas Newsletter and Dividend Growth Newsletter, as well as receive discounts on all of our modeling tools and products. Financial advisers and institutional investors have even more to choose from!

Click to Learn More about Valuentum

If you are already a subscriber, please login.

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content, click here to subscribe. You will be given immediate access to premium content on the site.